Citius Pharmaceuticals, Inc. Warrant, also called Citius Pharmaceuticals (Warrant), is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Read More It is currently advancing three proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; CITI-002, which provides anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and CITI-101, which is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. The listed name for CTXRW is Citius Pharmaceuticals, Inc. Warrant.